Xofluza Availability in India
Xofluza, an influenza antiviral medication, is not currently approved or marketed in India [1]. While Xofluza has been approved by regulatory bodies in other regions, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), there is no record of its approval by the Indian regulatory authorities [2].
Why Isn't Xofluza Available in India?
The absence of Xofluza in the Indian market is due to the need for specific regulatory approval from India's Central Drugs Standard Control Organisation (CDSCO) before any drug can be made available to patients [3]. Pharmaceutical companies must submit comprehensive data on safety, efficacy, and manufacturing quality for review. Without this approval, Xofluza cannot be legally manufactured, imported, or sold within India.
What are the Alternatives to Xofluza in India?
For influenza treatment in India, other antiviral medications are available. These typically include oseltamivir (marketed under brand names like Tamiflu) and zanamivir (marketed as Relenza) [4]. These drugs have been established in the Indian market and are prescribed by healthcare professionals to manage influenza symptoms and reduce the duration of illness.
How is Xofluza Different from Other Flu Treatments?
Xofluza, with the active ingredient baloxavir marboxil, represents a different class of antiviral compared to oseltamivir and zanamivir. It works by inhibiting cap-dependent endonuclease, an enzyme crucial for viral replication [5]. This mechanism of action differs from neuraminidase inhibitors like oseltamivir and zanamivir, which prevent the virus from releasing new viral particles from infected cells. Xofluza is typically administered as a single oral dose, which is a key differentiator in its dosing regimen compared to the multi-day oral or inhaled treatments of other antivirals [6].
When Might Xofluza Become Available in India?
The timeline for Xofluza's potential introduction into the Indian market depends on a new drug application being filed by the marketing authorization holder and subsequent review and approval by the CDSCO. There is no publicly announced timeline or ongoing regulatory process for Xofluza's approval in India at this time [1, 2].
Sources
1. DrugPatentWatch.com
2. U.S. Food and Drug Administration (FDA) approvals database.
3. Central Drugs Standard Control Organisation (CDSCO) website.
4. Indian national drug formulary and pharmaceutical market data.
5. Shionogi & Co., Ltd. and Roche product information.
6. U.S. National Library of Medicine, DailyMed.